Absci
@abscibio
Followers
2,364
Following
577
Media
254
Statuses
468
A generative #AI drug creation company with a mission to create better biologics for patients, faster.
Vancouver, WA
Joined September 2013
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
Arlington
• 560715 Tweets
All Out
• 527552 Tweets
Se o Twitter
• 340559 Tweets
Colorado
• 101166 Tweets
#CrisMorenaDay
• 97456 Tweets
Alexandre de Moraes
• 88589 Tweets
Pope
• 47856 Tweets
Valência
• 46209 Tweets
Vatican
• 44580 Tweets
De La Cruz
• 35896 Tweets
Fever
• 30065 Tweets
Bahia
• 28323 Tweets
Fireboy
• 28210 Tweets
#ラヴィット
• 27843 Tweets
lali
• 26863 Tweets
#AEWDynamite
• 24362 Tweets
NENA
• 24356 Tweets
Se o X
• 20086 Tweets
joaquin
• 19182 Tweets
Xandão
• 17498 Tweets
焼肉の日
• 14779 Tweets
Kaio Jorge
• 12215 Tweets
Bluesky
• 12102 Tweets
Adeus Twitter
• 11760 Tweets
Our new partnership with
@AstraZeneca
is further validation of our first-of-its-kind zero-shot generative AI model designed to create new and improved antibody therapeutics. Learn more about our new partnership in this
@FinancialTimes
article:
105
99
486
We're excited to announce our new collaboration with
@AstraZeneca
! This collaboration combines Absci's Integrated Drug Creation™ platform with AstraZeneca's expertise in oncology with the goal of accelerating the discovery of a potential new cancer treatment candidate.
104
68
284
We are on a mission to create better biologics for patients, faster. Are you ready to use your
#generativeAI
skills towards improving people's lives? Check out open
#AI
scientist roles:
26
39
253
Today, we announce a breakthrough in AI drug design: we are the first to design AND validate new therapeutic antibodies with zero-shot
#generativeAI
. De novo antibodies are here!
Read our preprint:
#JPM23
1
47
206
We're excited to collaborate with Caltech to bring
#AI
to the fight against HIV with the goal of developing affordable HIV vaccine therapies, supported by the
@gatesfoundation
Learn more here:
17
20
166
AI drug creation is poised to drive better antibody treatments into the clinic and ultimately to the patients who need them, pushing disease targets from the “undruggable” end of the spectrum to “not-drugged-yet.”
Here’s how.
2
29
151
Drug creation is hard, even for the most experienced. How is
#AI
helping to overcome challenges in drug discovery? Our pharma veteran Christian Stegmann discusses today’s key opportunities for bringing a Beatles-esque hit drug to market.
10
23
127
We’re excited to announce our new strategic partnership with
@precisionlifeAI
. Under the partnership, we’ll be working together to discover and develop a shared pipeline of biotherapeutics for up to five mutually agreed-upon targets and indications.
4
29
124
Attracting and retaining diverse talent is vital to building a successful organization and a positive, inclusive culture. Karin Wierinck, Absci’s new Chief People Officer, talks about building a workplace where everyone can be at their best in this blog.
9
14
95
Thrilled to share that Andreas Busch is joining us as Chief Innovation Officer. A leader in drug discovery R&D, his experience will bring tremendous value to our team as we pursue our mission to get patients better medicines, faster.
#CreateTheImpossible
4
10
81
First, we used
#AI
to optimize an antibody’s binding affinity and Naturalness score.
Then we used it to build novel antibodies.
Now we’ve turned AI towards codon optimization.
Read our latest preprint
@biorxivpreprint
#AI
#generativeAi
3
20
79
We are excited to announce our new collaboration with Almirall! We’ll be working together to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases.
2
19
78
What if the next transformative drug was not discovered, but created at the click of a button? Here’s our vision of the future — where drug discovery meets
#generativeAI
.
#JPM23
6
7
73
The data speaks for itself. Our
#generativeAI
models are performing significantly better than controls and constantly improving.
Validate our findings here:
2
12
68
De novo antibodies developed with zero-shot
#generativeAI
are here.
@GENbio
dives deeper and shares more about the results of our de novo antibody models. Read the full report from
@AlexWestchester
here:
0
8
52
Get behind the code with one of our
#AI
scientists revolutionizing antibody design.
Amir Shanehsazzadeh shares his insider perspective on the nascent AI
#drugdiscovery
field and our de novo breakthrough.
3
10
55
What can we realistically expect from AI drug design in the near term? Discover what the pharmaceutical industry really stands to gain from de novo antibodies in this blog featuring pharma veteran Dr. Andreas Busch.
#drugdiscovery
#generativeAI
4
11
51
Today, we announce a breakthrough in AI drug design: We’re the first to design AND validate new therapeutic antibodies with zero-shot
#generativeAI
.
Read about it in our preprint:
#JPM23
2
11
54
"When presented with the opportunity to join... and take part in developing what I believe to be one of most groundbreaking biopharma companies in the industry I knew it was simply too good an opportunity to pass up." - Andreas Busch
#CreatetheImpossible
0
0
42
Absci and
@M2GEN
are bringing AI
#DrugCreation
to the fight against cancer.
Our generative
#AI
platform will tap into M2GEN’s clinical data set, ORIEN AVATAR®, to create better cancer treatments for patients.
Learn more:
2
8
35
We are changing the paradigm from drug discovery to drug creation. CEO
@SeanRMcClain
& Chief AI Officer
@joshim5
share our
#GenerativeAI
approach to delivering breakthrough therapeutics at the click of a button, for everyone on the
@ARKInvest
FYI podcast:
0
3
27
ChatGPT for antibody design:
@Nature
shares the accelerating field of
#generativeAI
in the fight against disease.
Including our latest de novo manuscript as an example of the progress being made. Read it here:
0
6
29
Thanks
@Nasdaq
for welcoming us to ring the closing bell in celebration of our new partnerships with
@AstraZeneca
,
@AlmirallUS
, and
@precisionlifeAI
. We're excited to work with some of the premier companies in the pharma industry to bring new AI-driven medicines to patients.
4
3
20
We are pleased to announce that Absci will be unveiling encouraging pre-clinical findings on our novel anti-TL1A antibody program, ABS-101, at the J.P. Morgan Healthcare Conference this week. Watch the presentation live Thur. at 10:30AM PT or on demand at
1
3
17
We are delighted to welcome Prof Sir Mene Pangalos to our Board of Directors and as Co-Chair of our Scientific Advisory Board. Mene brings a wealth of experience from his distinguished career, most recently as EVP of BioPharmaceuticals R&D at AstraZeneca.
0
4
16
Zero-shot antibodies — a game-changer in biologic drug discovery.
We are the first to design and validate new therapeutic antibodies with zero-shot generative
#AI
. Read our preprint for more info and data:
#JPM23
#generativeAi
#drugdiscovery
3
3
17
We were inspired to meet so many like-minded AI innovators at
@NeurIPSConf
2023 last week. We participated in three technical workshops and showcased our new advancements in AI and antibody design. Learn more in our latest manuscripts:
1
1
17
The data speaks for itself. Our
#generativeAI
models are performing significantly better than controls and constantly improving.
Validate our findings here:
0
3
16
We're proud to be initiating IND-enabling studies on ABS-101, a de novo designed and optimized anti-TL1A antibody with a potential best-in-class profile. Read more:
#AI
#Biologics
#GenerativeAI
#DrugDiscovery
0
1
16
A milestone for protein-based
#drugdiscovery
- our generative
#AI
platform can create and wet-lab validate de novo antibodies in silico.
Thanks to
@GENbio
for the great synopsis - read it here:
0
2
15
Today’s featured breakthrough is our
#AI
model which we’ve developed to enable the design of high-affinity
#antibodies
. Learn more in our PR, and in the replay of Lead AI Scientist
@joshim5
’s presentation at
@NVIDIAHealth
’s
#GTC22
:
@NVIDIA
#Unlimit
0
4
8
We held our Inaugural R&D Day live from New York City today, where we unveiled our internal drug pipeline, including four wholly-owned assets focused on cytokine biology, each with the potential to reach IND filing in 2025. Watch a replay here:
1
0
13
Our incredible team of scientists took a big step in our mission to get better drugs to patients at unprecedented speeds. Read about it in our new preprint posted on
@biorxivpreprint
#drugdiscovery
#AI
#bioRxiv
Better drugs to patients faster. Read our new preprint on AI-assisted optimization of antibody binding affinity and naturalness and see how Absci is making rapid progress toward making this vision a reality.
#antibody
#ai
@biorxivpreprint
@abscibio
0
14
50
0
1
13
We are excited to share that we’ve entered into a multi-program collaboration with a stealth-mode antibody-drug conjugate (ADC) company, leveraging our Bionic Protein™ technology to help create more potent, less toxic
#biologics
.
#unlimit
#drugdiscovery
1
2
10
We’re looking for highly motivated AI Scientist Interns with experience in protein sequence and structure to join our team as we push the boundaries of science by combining generative AI and a state-of-the-art wet lab. Learn more:
#Hiring
#AI
#Biologics
2
1
11
“Absci really wants to become the Google Index search of protein-based
#DrugDiscovery
and biomanufacturing for large pharmas and biotechs,” Founder & CEO
@SeanRMcClain
shared with
@AlexWestchester
of
@GENbio
0
6
10
The impact of
#generativeAI
extends far beyond ChatGPT, most promisingly the field of drug discovery.
Join
@SeanRMcClain
as he shares our drive towards Creating Drugs at the Speed of AI during the
@SynBioBeta
conference May 23rd.
#SynBioBeta2023
1
6
11
Meet us at the JP Morgan Healthcare Conference next week, January 8-11, in San Francisco. Come learn more about the latest in AI drug creation, our recent partnerships, and how we can work together to potentially create novel biologics with superior attributes.
0
1
9
Special thanks to
@GovInslee
, the Absci Unlimiters, our partners and everyone else who joined us yesterday to cut the ribbon on our new Headquarters! We continue to grow every day, and we look forward to seeing the future of Absci unfold on our campus.
1
2
11
Today marks the one year anniversary of our IPO on the
@nasdaq
! The amount of progress we’ve made this year on our mission to get new medicines to patients at unprecedented speeds has been truly incredible to witness.
#Absci
#CreateTheImpossible
1
2
10
Absci is thrilled to be collaborating with
@NVIDIAHealth
to scale the advancements of our in-silico
#machinelearning
pipeline and accelerate protein-based drug discovery.
@NVIDIA
#Unlimit
0
8
11
At R&D Day this week, we unveiled our internal drug pipeline, recent technical and business milestones, and a peek into the future of AI drug creation. Check out our latest blog to learn more about some of the highlights:
0
1
11
✅ Use AI to optimize antibody binding affinity and naturalness score
✅ Use AI to build novel antibodies
✅ Use AI towards codon optimization to maximize therapeutic protein yield.
Read our latest preprint
@biorxivpreprint
#AI
#generativeAi
0
1
10
We recently hosted
@HannesStaerk
for our
#AbsciInvites
seminar series. Hannes presented his impressive work on Equibind, an extremely fast
#machinelearning
method for structural predictions of drug - protein complexes. Watch the recording here:
#unlimit
0
5
9
The secret is out, the promise of AI and natural language processing isn't a marketing trick to create digital art, the promise is in accelerating
#drugdiscovery
.
Thanks
@_KarenHao
for sharing some of our work in the
@WSJ
The best kept secret is that AI is the the future of biologics drug discovery. ChatGPT and DALL-E showed the public the power of AI, which is now being unleashed in
@abscibio
labs.
@_KarenHao
leaks the secret on Absci…
1
5
17
0
2
10
Meet our small but mighty team in Belgrade who is applying the latest in
#AI
and data science to help us deliver breakthrough therapies at the click of a button.
0
1
10
The incredible contributions
#WomenInScience
like Marie Curie, Dorothy Hodgkin, Gertrude Elion, and millions of others made inspire us every day at Absci. We believe
#EquityinScience
is critical as we continue to tackle new impossibles.
#February11
#unlimit
1
0
10
Excited that
@victorgreiff
,
@Hubert_Truebel
, and
@timlu
have joined our Scientific Advisory Board! Their experience in antibody design,
#synbio
& translational medicine will bring invaluable insights as we create better drugs at the speed of
#Ai
.
0
0
10
.
@GENbio
's
@AlexWestchester
recently spoke with Absci Founder & CEO
@SeanRMcClain
to learn more about some of the exciting recent happenings at Absci. Read the article here:
#AI
#Biologics
#DrugDiscovery
0
1
11
We’re excited to announce the opening of our new Absci
#AI
Research Lab (AAIR Lab) in
#Manhattan
’s Plaza District! This new space with views of
#CentralPark
is designed to energize and inspire innovation as we continue building our team of
#Unlimiters
.
1
1
10
In celebration of
#Blackhistorymonth2022
Absci would like to honor Katherine G. Johnson who passed away last year at the age of 101, for her pioneering work as a woman and minority in STEM. Her contributions in the field of mathematics and computer science continue to inspire us.
0
1
10
We were honored to receive
@oregonventure
’s top award this past weekend. Presented to our founder & CEO
@SeanRMcClain
and Absci for outstanding achievement in the field of entrepreneurship.
#AI
#drugdiscovery
#unlimit
#unlimiters
1
1
9
Recently we welcomed Byron Olsen as our new vice president of intellectual property.
Please give Byron a warm welcome with a like or a comment below!👇
0
0
9
When Tim Lu became a scientific adviser at Absci, he was surprised to learn just how advanced our E. coli platform had become. We caught up with Tim at
@SynBioBeta
2023 & he shared why this is so crucial for
#synbio
.
2
1
7
Are you a student pursuing a bachelor’s, master’s, or PhD? Do you want to work on the cutting edge of
#AI
and synthetic biology? The Absci 2022
#Internship
Program is accepting applications across multiple departments. Apply today!
#unlimit
#biotechjobs
0
9
8
Demystifying
#AI
: The Absci team (
@SeanRMcClain
, Matthew Weinstock, and
@joshim5
) had a fun conversation with Robyn Karnauskaus of
@TruistNews
and helped demystify the role of
#artificialintelligence
in
#drugdiscovery
.
#biologics
#deepmind
#unlimit
0
2
9
Absci founder & CEO
@SeanRMcClain
recently sat down for a chat at the Founder-Led Biotech Summit hosted by
@pillar_vc
and
@petribio
. Sean talked about the origins of Absci and much more in this conversation with
@kulesatony
.
#biotech
#ai
#unlimit
0
2
9
Excited to announce our drug discovery partnership with
@EQRxINC
. Together, we'll develop protein-based therapeutics across multiple disease indications like oncology.
Here’s to
#RemakingMedicine
to deliver the biggest possible impact for patients in need
0
2
8
Congratulations to Drs. Bertozzi, Medal, & Sharpless for winning the
#NoblePrize
! Their work on click chemistry has been integral to furthering the development of antibody-drug conjugates (ADCs) - powerful therapeutics in the fight against cancer.
0
2
7
Don’t miss
@SeanRMcClain
's fireside chat with
@amywebb
#today
at 4:05 PM PT at
@BuiltWithBio
2022.
#AI
#machinelearning
#biologics
Catch Absci founder & CEO
@SeanRMcClain
's fireside chat with
@amywebb
CEO of
@FTI
next Wednesday on the Main Stage at
@BuiltWithBio
2022. Great opportunity to learn more about how Absci is merging
#AI
and synthetic biology. Register here:
#machinelearning
0
4
5
0
4
8
Absci founder & CEO
@SeanRMcClain
will be presenting at the 40th Annual
@JPMorgan
#Healthcare
Conference on Monday, January 10th at 3:45 p.m. EST
#JPM22
Learn more:
0
1
8
Thanks for stopping by our HQ
@johncumbers
! We hope you enjoyed checking out how our Integrated Drug Creation™ platform combines the data to train, the AI to create, and the wet lab to validate better antibody candidates. We’ll see you at
#SynBioBeta2024
.
0
0
8
Join the Computational Antibody Discovery Symposium with
@TheAbSociety
on June 22
Featuring our Scientific Advisory Board member,
@victorgreiff
, sharing how developability parameters can be computed from the
#antibody
sequence and structure.
0
1
8
ICYMI - Absci CTO Matthew Weinstock and VP of
#AI
Research Greg Hannum spoke with
@ZDNet
about developing AI models that expand therapeutic possibilities with biologic
#drugdiscovery
innovation. Check out their interview with
@TiernanRayTech
:
#biotech
0
4
8
Join our SVP of Drug Creation,
@CMStegmann
, and his talk on 𝙏𝙝𝙚𝙧𝙖𝙥𝙚𝙪𝙩𝙞𝙘 𝘼𝙣𝙩𝙞𝙗𝙤𝙙𝙮 𝘿𝙚𝙨𝙞𝙜𝙣 𝙐𝙨𝙞𝙣𝙜 𝙂𝙚𝙣𝙚𝙧𝙖𝙩𝙞𝙫𝙚 𝘼𝙄 tomorrow in Zurich at the
@carterra_bio
Symposium on High-Throughput Drug Discovery
0
0
8
A drug discovery first: Absci designs AND validates new therapeutic antibodies with the use of zero-shot generative AI.
Absci Founder & CEO Sean McClain will share the details 5:15pm PST today at the J.P. Morgan Healthcare Conference 2023.
#JPM2023
#JPMHealthcare
1
0
8
Join us next week at
@AntibodyEngIC
2023 in San Diego. We’ll be presenting a poster on “Antibody Design Using Generative AI” (
#119
) and discussing our work on de novo antibody creation and lead optimization in silico. Learn more at the event site here:
1
2
5
.
@SynBioBeta
's
@johncumbers
recently spoke to Absci Founder & CEO
@SeanRMcClain
about his experience speaking to lawmakers on Capitol Hill and why Absci’s new partnership with
@AstraZeneca
is such an exciting moment for AI drug creation. Listen here:
0
1
8
Absci is thrilled to announce that we have won the Health Care of the Future Innovation Award from the
@PDXBIZJournal
! This award recognizes our groundbreaking work in drug creation, which uses
#GenAI
to accelerate the development of new, more effective treatments for patients.
0
0
8
We are excited to welcome our new Chief AI Officer Amaro Taylor-Weiner to the team! Amaro will be leading our AI teams, helping develop Absci’s first-in-class generative AI platform to design and validate de novo therapeutic antibodies. Learn more:
1
0
8
Our zero-shot antibody designs from generative
#AI
are an example of AI identifying drug candidates that no one has ever seen — unlocking the potential for faster, cheaper pharmaceuticals. Thanks for the shout-out,
@techreview
!
1
2
7
Can you dig it?
Join us this Thursday, August 17th, at the
@LifeScienceWA
's Annual Summer Social. Let's boogie down at the Disco! 🕺
0
2
7
Great to see a packed room & robust conversations around ‘naturalness’ & binding affinity in the
#AI
track for antibody design during
#antibodyENG
1
1
7
We don't promote hype — we promote progress.
Our success using
#generativeAI
to create de novo antibodies is a testament to that. Let's focus more on breakthroughs, as they bring hope to patients and reshape the landscape of
#drugdiscovery
0
0
7
Our
#AI
-first approach has the potential to transform
#drugdiscovery
, and now its more accessible to innovators across the world with our expansion in Europe.
@SeanRMcClain
recently celebrated the opening of our office in Zug, Switzerland. Learn more:
1
1
7
Help us welcome our newest Unlimiter, our Head of Translational Research, Amer-Denis Akkad! Give a like and leave a comment below for Amer-Denis on his first week at Absci 👇
1
0
7
Join Absci founder & CEO
@SeanRMcClain
, CTO Matthew Weinstock, and other leaders in
#AI
drug discovery for a panel on utilizing
#deeplearning
& quantum physics to speed drug development. Live at the
@TruistNews
AI Symposium Tuesday at 10:10 AM ET.
#Unlimit
0
3
7
Tune in today at 12 pm PT to hear from our founder and CEO
@SeanRMcClain
and other biotech CEOs at this year’s Founder-Led Biotech Summit. It’s not too late to register for free!
#AI
#biotech
#drugdiscovery
0
3
7
Join Absci Founder & CEO
@SeanRMcClain
at the Fortune Brainstorm AI conference in San Francisco next Monday. He’ll be joining executives from Pfizer and Kaiser Permanente for a panel discussion on the latest advancements in AI for pharma and healthcare.
1
1
6
We are helping Caltech use
#generativeAI
to accelerate the development of affordable vaccines in the fight against HIV, with generous support form the Bill and Melinda Gates Foundation.
Read more in
@politico
:
2
1
7
Today, it is rap lyrics a la
#chatgpt
, but down the road generative
#AI
has potential generate formulas for novel biologics, with highly specific powers tuned to the biology of illness. Read more about our evolution from
@TiernanRayTech
1
0
7
ICYMI: An audio & video recording of Absci founder & CEO Sean McClain’s presentation at the 40th Annual
@JPMorgan
#Healthcare
Conference is now available on our YouTube Channel:
#JPM22
#ai
#drugdiscovery
#antibodies
0
0
7
We’re honored to be featured as one of the
@FortuneMagazine
50 AI innovators today. The award highlights how the integration of our wet lab and
#AI
technologies is driving the development of our Integrated Drug Creation platform.
#Biologics
#DrugDiscovery
0
1
7